Navigation Links
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Date:11/5/2007

aily. When initiating statin therapy or switching from another statin therapy, the appropriate CRESTOR starting dose should first be utilized, and only then titrated according to the patient's individualized goal of therapy. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of this combination. Combination therapy with rosuvastatin and gemfibrozil should generally be avoided. CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy, such as renal impairment, advanced age, and inadequately treated hypothyroidism. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CRESTOR is generally well-tolerated. Adverse reactions have usually been mild and transient. The most frequent adverse events thought to be related to CRESTOR were myalgia (3.3%), constipation (1.4%), asthenia (1.3%), abdominal pain (1.3%) and nausea (1.3%).

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has be
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AAHC Examines Nations Clinical Trials Infrastructure
2. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. DNA Test Predicts Harmful Effects of Cancer Drug
5. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... is an opportune time to find the best plan ... Dec. 15 Through the end of the ... important decisions about their health coverage. This is ... which health benefits they will sign up and pay ... a critical part of this decision, says Independent Retail ...
(Date:12/15/2009)... -- Dynatronics Corporation (Nasdaq: DYNT ... agreement to provide therapy equipment and rehab supplies ... network of physical, occupational and speech therapy clinics. ... Therapy Providers," said Larry K. Beardall, executive vice ... vast network of 1,100 clinics is the largest ...
(Date:12/15/2009)... Reportlinker.com announces that a new market research ... Boehringer Ingelheim GmbH: PharmaVitae Profile ... ,, This analysis examines the historical ... the Rx pharmaceutical sector. The profile encompasses ... assessment of financial performance, with 1-6 year ...
Breaking Medicine Technology:Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Immunotherapy Demonstrates Long Term Success in Treating Lymphoma 60471 1Immunotherapy Demonstrates Long Term Success in Treating Lymphoma 60471 2Immunotherapy Demonstrates Long Term Success in Treating Lymphoma 60471 3Immunotherapy Demonstrates Long Term Success in Treating Lymphoma 60471 4Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease 60466 1Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease 60466 2Switching immunosuppressants reduces cancer risk in kidney 60461 1Switching immunosuppressants reduces cancer risk in kidney 60461 2
... Replidyne, Inc.,(Nasdaq: RDYN ) announced today that President ... the New and Powerful Anti-infectives,panel at the RBC Capital ... at 11:00 am ET on Thursday, December 13, 2007 ... A live audio webcast of the panel discussion will ...
... 5 Genzyme Corp.,(Nasdaq: GENZ ) announced ... phase 2 clinical trial examining the safety and ... patients with,acute myelogenous leukemia (AML) who are unlikely ... study are expected to provide substantial,evidence for expanding ...
Other Medicine Technology:Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 3Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 4Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 5Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 6
(Date:12/15/2009)... Preserving State Authority, Ban on Annual Benefit Limits, ... 15 Consumer Watchdog condemned the removal ... 55 and the public option from the U.S. ... that the Senate must still make three essential ... ceding the entire health care system to the ...
(Date:12/15/2009)... Alto Networks(TM), the network security company, today announced ... next-generation firewalls for accurate threat prevention on its ... over applications such as peer-to-peer file sharing. ,, ... eight facilities on five campuses. The university was ... academic schools and institutions throughout Japan. It is ...
(Date:12/15/2009)... WASHINGTON, Dec. 15 Our Lady of Lourdes ... New Jersey hospitals, has agreed to pay the United ... defrauded Medicare, the Justice Department announced today. The two ... in Camden, N.J., and Lourdes Medical Center of Burlington ... a defendant in a suit brought by a whistleblower, ...
(Date:12/15/2009)... levels of leptin associated with lower dementia risk, research ... blood levels of leptin, a hormone that regulates appetite, ... "Hopefully, in 10 or 15 years this may be ... the risk of Alzheimer,s disease," said senior study author ... Boston University School of Medicine. "Or it may be ...
(Date:12/15/2009)... have released some sobering statistics concerning the parallel rise in diabetes ... an effective means of combating this trend afflicting their workforce. ... ... of diabetes are climbing across America due in large part to ... American Diabetes Association has stated that the rate of diabetes could ...
Breaking Medicine News(10 mins):Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3
... Vision Care and U.S. Soccer Federation team up to give ... athletes a performance edge with better vision, JACKSONVILLE, Fla., ... marketer of ACUVUE(R) Brand Contact Lenses,today announced it is an ... body for the sport of soccer in the United,States., ...
... PARK, Calif., March 17 Exponent, Inc.,(Nasdaq: EXPO ) ... CFO of Exponent will participate at the following,conferences:, ... Investor Forum Date: Tuesday, March 25, 2008 ... Location: The Grand Hyatt, New York City, New ...
... Inc.,(Nasdaq: ANSS ), a global innovator of ... processes, today announced it is a,sponsor of the ... Museum of,Natural History in Pittsburgh. This is the ... accurate, immersive environments that are,composed of original fossil ...
... Bark Improves Senior Citizens Cognitive ... ... research accepted for,publication in the Journal of Psychopharmacology, demonstrates,Pycnogenol(R), (pic-noj-en-all), an ... improves the memory of senior citizens.,The study results revealed Pycnogenol(R) improved ...
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") announced ... tender offer to purchase,any and all of its outstanding ... which $250 million in aggregate principal amount was,outstanding as ... made,pursuant to an Offer to Purchase dated February 29, ...
... antagonist of CCR9, a chemokine receptor believed ... to play a critical role in Crohn,s disease -, ... ) today announced the advancement of,MLN3126, a new product candidate, ... a selective antagonist of CCR9, a,chemokine receptor known to be ...
Other Medicine News:Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 2Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:New Study: Pycnogenol(R) Improves Memory in Elderly 2Health News:New Study: Pycnogenol(R) Improves Memory in Elderly 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 5Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 2Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: